Cinacalcet normalizes serum calcium in a double blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery

European Journal of Endocrinology

Volumn 172, Issue 5, 2015, Pages 527-535

  Khan, Aliya ^a   Bilezikian, John ^b   Bone, Henry ^c   Gurevich, Andrey ^d   Lakatos, Peter ^e   Misiorowski, Waldemar ^f   Rozhinskaya, Liudmila ^g   Trotman, Marie Louise ^d   Tóth, Miklós ^e  

^a MCMASTER UNIVERSITY   (Canada)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c Michigan Bone and Mineral Clinic   (United States)

^d AMGEN INC   (United States)

^e SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^f MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^g ENDOCRINOLOGY RESEARCH CENTRE   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE; PLACEBO; NAPHTHALENE DERIVATIVE; PHOSPHORUS;

AGED; ANOREXIA; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DECREASED APPETITE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHASE 3 CLINICAL TRIAL; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT OUTCOME; ADULT; BIOASSAY; BLOOD; CLINICAL TRIAL; COMPLICATION; CONTRAINDICATIONS; HYPERCALCEMIA; HYPERPARATHYROIDISM; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROIDECTOMY; PHOSPHORUS;

EID: 84929505324     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0877     Document Type: Article

References (34)

1. Silverberg SJ & Bilezikian JP. Evaluation and management of primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 1996 81 2036-2040. (doi:10.1210/jcem.81.6.8964825)
2. Marcocci C & Cetani F. Update on the use of cinacalcet in the management of primary hyperparathyroidism. Journal of Endocrinological Investigation 2012 35 90-95. (doi:10.3275/8112)
3. Eastell R, Arnold A, Brandi ML, Brown EM, DeAmour P, Hanley DA, Rao DS, Rubin MR, Goltzman D, Silverberg SJ et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. Journal of Clinical Endocrinology and Metabolism 2009 94 340-350. (doi:10.1210/jc.2008-1758)
4. Bilezikian JP, Khan AA & Potts JT. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. Journal of Clinical Endocrinology and Metabolism 2009 94 335-339. (doi:10.1210/jc.2008-1763)
5. Zhao L, Liu JM, He XY, Zhao HY, Sun LH, Tao B, Zhang MJ, Chen X, Wang WQ & Ning G. The changing clinical patterns of primary hyperparathyroidism in Chinese patients: data from 2000 to 2010 in a single clinical center. Journal of Clinical Endocrinology and Metabolism 2013 98 721-728. (doi:10.1210/jc.2012-2914)
6. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C & Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. Journal of Clinical Endocrinology and Metabolism 2014 99 3561-3569. (doi:10.1210/jc.2014-1413)
7. Udelsman BV & Udelsman R. Surgery in primary hyperparathyroidism: extensive personal experience. Journal of Clinical Densitometry 2013 16 54-59. (doi:10.1016/j.jocd.2012.11.007)
8. Ruda JM, Hollenbeak CS & Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngology-Head and Neck Surgery 2005 132 359-372. (doi:10.1016/j.otohns.2004.10.005)
9. Wermers RA, Khosla S, Atkinson EJ, Grant CS, Hodgson SF, OeFallon WM & Melton LJ III. Survival after the diagnosis of hyperparathyroidism: A population-based study. American Journal of Medicine 1998 104 115-122. (doi:10.1016/S0002-9343(97)00270-2)
10. Brown EB. Mechanisms underlying extracellular calcium homeostasis. In Handbook of Parathyroid Diseases: A Case Based Practical Guide, 1st edn, ch 1, pp 1-18. Eds AA Khan & OH Clark. New York, USA; Dordrecht, Germany; Heidelberg, Germany; London, UK: Springer, 2012. (doi:10.1007/978-1-4614-2164-1)
11. Schwarz P, Body JJ, Càp J, Hofbauer IC, Farouk M, Gessl A, Kuhn JM, Marcocci C, Mattin C, Muñoz Torres M et al. PRIMARA: A prospective descriptive observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice. European Journal of Endocrinology 2014 171 727-735. (doi:10.1530/EJE-14-0355)
12. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. Journal of Pharmacology and Experimental Therapeutics 2004 308 627-635. (doi:10.1124/jpet.103.057273)
13. Khan A, Grey A & Shoback D. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. Journal of Clinical Endocrinology and Metabolism 2009 94 373-381. (doi:10.1210/jc.2008-1762)
14. Peacock M, Bilezikian JP, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S & Shoback D. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. Journal of Clinical Endocrinology and Metabolism 2011 15 E9-E18. (doi:10.1210/jc.2010-1221)
15. Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, Henzen C, Cheng S, Sterling LR, Lu J et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2009 94 2766-2772. (doi:10.1210/jc.2008-2640)
16. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drueke TB, Cunningham J, Sherrard DJ, McCary LC et al. Achieving NKF-K/DOQI, bone metabolism and disease treatment goals with cinacalcet HCl. Kidney International 2005 67 760-771. (doi:10.1111/j.1523-1755.2005.67139.x)
17. Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC, Schwanauer LE, Olson KA, Klassen P & Bilezikian JP. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2007 92 3803-3808. (doi:10.1210/jc.2007-0585)
18. Pasieka JL, Parsons LL, Demeure MJ, Wilson S, Malycha P, Jones J & Krzywda B. Patient-based surgical outcome tool demonstrating alleviation of symptoms following parathyroidectomy in patients with primary hyperparathyroidism. World Journal of Surgery 2002 26 942-949. (doi:10.1007/s00268-002-6623-y)
19. Stewart AL & Ware JE Jr. Measuring functioning and well-being: the medical outcomes study approach. Duke University Press, 1992.
20. Ware SE Jr & Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992 30 473-483. (doi:10.1097/00005650-199206000-00002)
21. Houillier P & Paillard M. Calcium-sensing receptor and renal cation handling. Nephrology, Dialysis, Transplantation 2003 18 2467-2470. (doi:10.1093/ndt/gfg420)
22. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA & Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2005 90 135-141. (doi:10.1210/jc.2004-0842)
23. PeacockM, Bolognese MA, BorofskyM, Scumpia S, Sterling LR, Cheng S & Shoback D. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. Journal of Clinical Endocrinology and Metabolism 2009 94 4860-4867. (doi:10.1210/jc.2009-1472)
24. Bilezikian JP, Potts JT Jr, Fuleihan G, Kleerekoper M, Neer R, PeacockM, Rastad J, Silverberg SJ, Udelsman R & Wells SA. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: A perspective for the 21st century. Journal of Clinical Endocrinology and Metabolism 2002 87 5353-5361. (doi:10.1210/jc.2002-021370)
25. Perrier ND, Balachandran D, Wefel JS, Jiminez C, Busaidy N, Morris GS, DongW, Jackson E, Weaver S, Gantela S et al. Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with "asymptomatic" primary hyperparathyroidism. Surgery 2009 146 1116-1122. (doi:10.1016/j.surg.2009.09.034)
26. Filopanti M, Verga U, Ermetici F, Jimenez C, Busaidy N, Morris GS, Dong W, Jackson E, Weaver S, Gantela S et al. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly. European Journal of Endocrinology 2012 167 157-164. (doi:10.1530/EJE-12-0117)
27. Grey A, Lucas J, Horne A, Gamble G, Davidson JS & Reid IR. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. Journal of Clinical Endocrinology and Metabolism 2005 90 2122-2126. (doi:10.1210/jc.2004-1772)
28. Tucci JR. Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. European Journal of Endocrinology 2009 161 189-193. (doi:10.1530/EJE-08-0901)
29. Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ et al. Alendronate in primary hyperparathyroidism: A double-blind, randomized, placebocontrolled trial. Journal of Clinical Endocrinology and Metabolism 2004 89 3319-3325. (doi:10.1210/jc.2003-030908)
30. Faggiano A, Di Somma C, Ramundo V, Severino R, Vuolo L, Coppola A, Panico F, Savastano S, Lombardi G, Colao A et al. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. Endocrine 2011 39 283-287. (doi:10.1007/ s12020-011-9459-0)
31. Weber T, Eberle J, Messelhauser U, Schiffmann L, Nies C, Schabram J, Zielke A, Holzer K, Rottler E, Henne-Bruns D et al. Parathyroidectomy, elevated depression scores, and suicidal ideation in patientswith primary hyperparathyroidism: results of a prospective multicenter study. JAMA Surgery 2013 148 109-115. (doi:10.1001/2013.jamasurg.316)
32. Weber T, Keller M, Hense I, Pietsch A, Hinz U, Schilling T, Nawroth P, Klar E & Buchler MW. Effect of parathyroidectomy on quality of life and neuropsychological symptoms in primary hyperparathyroidism. World Journal of Surgery 2007 31 1202-1209. (doi:10.1007/s00268-007-9006-6)
33. Talpos GB, Bone HG III, Kleerekoper M, Phillips ER, Alam M, Honasoge M, Divine GW & Rao DS. Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: patient description and effects on the SF-36 health survey. Surgery 2000 128 1013-1020. (doi:10.1067/msy.2000.110844)
34. ShobackDM, Bilezikian JP, Turner SA,McCary LC, GuoMD&PeacockM. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2003 88 5644-5649. (doi:10.1210/jc.2002-021597)